Please assess the completion status of the following clinical trial:

Trial Title: An Interventional Study to Assess the Efficacy and Safety of Oxycodone/Naloxone in Korean Patients With Spinal Disorders

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: SUPPORTIVE_CARE
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female ≥ 20 and \<80 years of age~* Patients who have spinal disorders related pain for over 90days~* Patients who have moderate to severe pain intensity which is not controlled with weak opioids or NSAIDs: NRS ≥ 4~* Naïve patients for Oxycodone/Naloxone~* Naïve patients for strong opioid~* Patients who signed a written informed consent form~Exclusion Criteria:~* Women of child-bearing potential, defined as all women physiologically capable of becoming pregnant.~* Pregnant or nursing (lactating) women, where pregnancy is defined as the state of a female after conception and until the termination of gestation, confirmed by a positive urine pregnancy test~* Patients with known hypersensitivity to Oxycodone/Naloxone or to any of the excipients~* Patients with severe respiratory depression with hypoxia and/or hypercapnoea~* Patients with severe chronic obstructive pulmonary disease~* Patients with cor pulmonale~* Patients with severe bronchial asthma~* Patients who have been diagnosed or is suspected of having paralytic or obstructive ileus.Patients with moderate to severe hepatic impairment~* Targin(R) product contains lactose. Patients with rare hereditary problems of galactose intolerance, Lapp lactase deficiency or glucose-galactose malabsorption should not take~* Abnormal aspartate aminotransferase (AST; SGOT), alanine aminotransferase (ALT; SGPT), or alkaline phosphatase levels (\>2.5 times the upper limit of normal, it is allowed \>5 times the upper limit of normal in case of transition in liver) or an abnormal total bilirubin and/or creatinine level (s)(greater than 1.5 times the upper limit of normal), gamma glutamyl transpeptidase (GGT or GGTP) ≥ 3 times the upper limit of normal~* Patients with uncontrolled seizures~* Requiring interventional treatment for pain such as neurodestructive procedure or regional infusion~* Patients with increased intracranial pressure~* In the investigator's opinion, subjects who are receiving hypnotics or central nervous system (CNS) depressants that may pose a risk of additional CNS depression with opioid study medication~* Patients with myxodema, not adequately treated hypothyroidism or Addisons disease~* Patients receiving opioid substitution therapy for opioid addiction (e.g. methadone or buprenorphine)~* Clinically significant impairment of cardiovascular, respiratory and renal function~* Major surgery within 1 month prior to screening or planned surgery~* Mainly pain originated other than spinal disorders disease~* Non-malignant patients or cancer patients who are receiving any oncology treatment that could affect the measure of pain control~* Patients with uncontrolled constipation regardless of laxative use and/or laxative type~* With a disability that may prevent the patient from completing all study requirements and in particular, interfere with 24hrs pain intensity score~* Patients known to have, or suspected of having a history of drug abuse~* Patients with history of opioid or drug dependence~* Any situation where opioids are contraindicated~* Patient who needs acute dose titration or whose pain intensity fluctuate significantly in a short period according to investigator's judgment~* Having used other investigational drugs at the time of enrollment~No additional exclusions may be applied by the investigator, in order to ensure that the study population will be representative of all eligible patients.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oxycodone/Naloxone (Type: EXPERIMENTAL): Single-arm study

Based on this trial design, predict the completion outcome and termination type (if applicable).